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patients with ICD-9CM codes for schizophrenia (295.xx). Records were assessed for
a period of 18 months (6-month pre-index period with no antipsychotics plus 12-
month post-index period). A medication possession ratio (MPR) of  80% or a pro-
portion of days covered (PDC) of 80%was considered adherent. RESULTS: A total
of 1,470 patients met inclusion criteria; 31% (n462) had an MPR  80%. Based on
MPR, 30% (405/1338) in the oral cohort and 43% (57/132) in the injectable cohort
were adherent. Logistic regression analyses adjusting for demographic covariates
(age, gender, race) showed that patients in the injectable cohort were about 77%
more likely to be adherent based on MPR (OR1.77, 95% CI1.22-2.56, p0.05)
compared to the oral cohort. Of the demographic covariates, race (Blacks  less
adherent; p0.001) was the only significant covariate. Similarly, increased adher-
ence in the injectable cohort (OR1.81, 95% CI1.24-2.63, p0.05) was also found
using PDC, where race (Blacks less adherent; p0.001) and gender (women less
adherent; p0.05) were significant. CONCLUSIONS: Overall, less than one-third of
all patients were adherent (MPR  80%) one year after their index date. Patients
taking long-acting injectable risperidone had higher rates of adherence compared
to patients taking oral risperidone alone. In addition, this findingwas confirmed by
PDC, which has been shown to be a more conservative calculation of adherence in
patients with schizophrenia.
PMH46
THE EFFECT OF ANTIPSYCHOTIC ADHERENCE ON ADHERENCE TO DIABETES,
HYPERLIPIDEMIA, AND HYPERTENSION MEDICATIONS AND ASSOCIATED
HEALTH SERVICE UTILIZATION
Farley J1, Hansen R2, Yu-Isenberg K3, Maciejewski M4
1University of North Carolina, Chapel Hill, NC, USA, 2Auburn University, Auburn, AL, USA,
3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 4Duke University Medical
Center, Durham, NC, USA
OBJECTIVES: To examine the association of antipsychotic adherence with adher-
ence to medications for diabetes, hyperlipidemia, and hypertension and with
healthcare utilization.METHODS:Medstat Medicaid claims data were used to gen-
erate cohorts of patients with schizophrenia newly initiating a second generation
antipsychotic and using medications for diabetes, hypertension, and hyperlipid-
emia. Quarterly (Q) adherence measurements were calculated for each patient to
capture initiation (Q1), continuation (Q2-Q4), andmaintenance (Q5-Q8) periods via
the proportion of days covered (PDC)  80%. Generalized estimating equations
examined the association of initiation period antipsychotic adherencewith comor-
bid medication adherence and health service utilization during the continuation
phase. Similarly, continuation phase antipsychotic adherence was used to predict
parallel maintenance phase outcomes. RESULTS: Patients adherent to antipsy-
chotic treatment during initiation (Q1) were more adherent to medications for
diabetes [Odds Ratio (OR) 1.77; 95% CI(0.95, 3.29)], hypertension [1.36, (0.91, 2.04)],
and hyperlipidemia [2.24, (1.02, 4.90)] during the continuation phase. Similarly,
continuation phase antipsychotic adherence was associated with higher adher-
ence to medications for diabetes [4.99, (2.85, 8.71)], hypertension [7.51, (5.07,
11.12)], and hyperlipidemia [5.68, (2.71, 11.92)] during the maintenance phase.
Higher antipsychotic adherence during the continuation phase also was asso-
ciated with more frequent outpatient visits [Incident Rate Ratio  1.53 (1.21,
1.94), 1.57 (1.35, 1.82), 1.63 (1.28, 2.07)], less frequent inpatient admission [OR 
0.73 (0.43, 1.26), 0.70 (0.49, 1.00), 0.87 (0.49, 1.54)] and less frequent emergency
department use [OR  0.68 (0.42, 1.10), 0.58 (0.47, 0.78), 0.76 (0.47, 1.25)] during
the maintenance phase among patients with diabetes, hypertension, and hy-
perlipidemia respectively. CONCLUSIONS: Antipsychotic adherence was associ-
ated with better adherence to medications for chronic comorbid health conditions
as well as a trend toward lower inpatient and emergency department use over a 2
year period. These findings suggest potential benefits to antipsychotic adherence
beyond mental health management.
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OBJECTIVES: Buprenorphine-medication assisted treatment (B-MAT) is an effec-
tive treatment for OD, but is hypothesized to have the greatest impact on those
patients who are compliant. This analysis was conducted to compare economic
costs and benefits between B-MAT compliant and non-compliant OD members.
METHODS: A longitudinal, multivariate analysis was conducted using service use
claims data among a sample of Aetna members with full benefit coverage and at
least one diagnoses of OD during the 48monthmeasurement period (Q1 2006 to Q4
2009). Medication possession ratio (MPR) was calculated for the sample (n  725).
Memberswith anMPR .80were classified as compliant (n 324), with the balance
classified as non-compliant (n  401). Two six-month measurement periods were
constructed around the index date. RESULTS: After B-MAT induction, compared to
non-compliant B-MATmembers, compliantmembers increased their total number
of prescriptions filled by an average of 2.57 per member (P  0.007). However,
B-MAT compliant members showed decreases in inpatient hospital admissions
(0.62), inpatient hospital days (4.77), and emergency room visits (0.42; P’s
0.001). Concerning healthcare costs, compliant B-MAT members increased their
spend at the pharmacy compared to non-compliant B-MATmembers by $1,059 per
member (P  0.001), but decreased inpatient hospital costs ($9,623) and ER costs
($1,068; P’s  0.001). Overall, compliant B-MAT members spent a total of $14,448
less (P 0.001) per member over the first six months of treatment. CONCLUSIONS:
Though compliant B-MAT patients incur higher pharmacy and costs, they use
fewer expensive health care services in other areas, resulting in an overall positive
cost-benefit conclusion for B-MAT. Compliance with medication-assisted treat-
ment is essential for patient recovery, but given that less than half of the sample
had an MPR  .80, additional treatment ancillaries or disease management pro-
grams may be needed to increase patient compliance.
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OBJECTIVES:Bipolar Disorder (BP) is a condition inwhich adherence to therapy and
medication is vital to help patients avoid severe social and emotional problems.
Patient beliefs are one of many important factors that determine patient adher-
ence.We sought to systematically review the literature on the role of patient beliefs
about their BP, their medications, and their health care team, and the impact these
beliefs have on adherence to both medication and therapy.METHODS: A system-
atic literature review was performed using Medline, PubMed and PsychInfo. The
eligibility criteria for studies were as follows: studies published from January 1,
2000 through March 28, 2010; patient sample comprised BP patients only; adher-
ence to either medication or therapy was a primary study outcome; measures of
patient beliefs or belief system were reported. Titles and abstracts were screened
for potentially relevant studies. RESULTS: A total of 10 studies met our study in-
clusion criteria; study participants usually consisted of BP patients recruited from
outpatient clinics and similar sites. A wide variety of beliefs ranging from disease
denial, doubt ofmedication efficacy, fear of side effects, desire for alternative treat-
ment, and conflicting religious ideas all had a negative impact on adherence to
medication and therapy. A strong patient-provider relationship, belief that medi-
cation was necessary, and belief that benefits outweighed risks were identified as
beliefs that positively impacted patient adherence.CONCLUSIONS:Themajority of
primary literature on BP patient beliefs and adherence focuses mostly around the
patient-provider relationship, and concerns aboutmedication side effects. There is
a lack of studies that deal with other patient beliefs such as how they feel about
their diagnosis, their belief in medication efficacy, and how their spiritual beliefs
affect adherence. A better understanding of patient beliefs may help improve cli-
nicians’ counseling techniques, and help them to encourage greater adherence to
medication and therapy.
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OBJECTIVES:The Illness PerceptionQuestionnaire (IPQ)was designed as ameasure
of illness perception and has been adapted on many occasions for use in distinct
domains. More recently modified versions of the IPQ have been used to determine
the illness perceptions of people with schizophrenia and their carer’s. The current
investigation examined the utility of a modified version of the IPQ to assess
changes in mental health practitioners’ illness perceptions about schizophrenia
after completing postgraduate training in psychosocial interventions. METHODS:
A total of 245 mental health practitioners completed a modified version of the IPQ
pre and post training in a psychosocial interventions postgraduate course. The
structure of the questionnaire was evaluated using confirmatory factor analysis
and the internal consistencies of sub-scaleswithin the instrumentwere examined.
RESULTS: Model fit indices revealed a poor fit to the data across all of the models
evaluated (CFI  0.51-0.80, RMSEA  0.12-0.20). Internal consistency analysis re-
vealed a number of sub-scales (0.53-0.78) in the instrument to also have poor psy-
chometric qualities. CONCLUSIONS: The suitability of the modified version of the
IPQ for evaluating the impact psychosocial intervention training on changes in
illness perceptions of schizophrenia in mental health practitioners is not sup-
ported based on psychometric criteria. The need to develop a valid and reliable
measure to assess the illness perceptions of health professionals have of patients
in their care remains a priority.
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OBJECTIVES: This study was undertaken to estimate utility values for alternative
treatment intervals for long acting antipsychotic intramuscular injections for the
treatment of schizophrenia. METHODS: Vignettes were developed using the pub-
lished literature and an iterative consultation process with expert clinicians and
patient representative groups. Four vignettes were developed. The first was a vi-
gnette of relapsed/untreated schizophrenia. The other three vignettes presented a
standardised picture of well managed schizophrenia with variations in the inter-
vals between injections: once every 2weeks, 4-weeks and 3months. The time trade
off (TTO) approach was used to obtain utility values for the vignettes. As a societal
perspective was sought, a representative sample of individuals from across the
community (Sydney, Australia) was recruited. Ninety-eight people completed the
TTO interview. The vignettes were presented in random order to prevent possible
ordering effects. RESULTS: A clear pattern of increasing utility was observed with
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increasing time between injections. Untreated schizophrenia was rated as very
poor health-related quality of life with a mean (median) utility of 0.27 (0.20). The
treated health states were rated at much higher utilities and were statistically
significantly different (p0.001) from each other: (1) 2-weekly: mean (median) util-
ity  0.61 (0.65); (2) 4-weekly: mean (median) utility  0.65 (0.70); (3) 3-monthly:
mean (median) utility 0.70 (0.75). CONCLUSIONS: This study has provided robust
data indicating that approximately a 0.05 utility difference exists between treat-
ment options, with the highest utility assigned to 3-monthly injections.
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OBJECTIVES: Depression exerts significant morbidity in homebound elders. While
antidepressant medications are effective, little data exist on non-pharmacological
support programs. Beat the Blues (BTB) is a non-pharmacological intervention de-
signed to teach community dwelling depressed African Americans elders coping
skills. BTB was tested in an 8-month randomized two-group experimental design
(treatment vs. wait list control). This analysis examines relationships between
health utility and baseline characteristics of participants.METHODS: Patientswere
enrolled in 2009 and 2010 and eligible if they had depressive symptoms (i.e., PHQ-9
score 5), were African American, 55 years, English speaking, and cognitively
intact (MMSE 24). Data included demographics, co-morbidities, functionality
(ADL, IADL, and mobility), and health utility which were converted from EQ-5D
scores using US scoring algorithm. Regression analyses were conducted to assess
the relationship between health utility and relevant variables with focus on the
relative impact of depression score, with and without adjusting for the study
variables. RESULTS: In the sample (n86), the average age was 68, most were
female (77%), unmarried (92%), non-working (89%), had an average of 6.5 health
conditions (range 1-15), and taking at least onemedication for depression, anxiety,
sleep, or pain. The mean EQ-5D utility index score was 0.56 (SD 0.2); mean PHQ-9
scorewas 12.6 (moderate depression; SD 4.9). EQ-5D index scoreswere significantly
related to PHQ9 score, gender, diabetes, asthma, stroke,multiple sclerosis,memory
problems (p.05) and highly related to functionality (IADL, mobility), foot prob-
lems, number of comorbidities (p.005). After adjusting for patients’ age, educa-
tion, and gender, EQ-5D utility score was significantly decreased as patients had
mobility difficulty, high PHQ9 score, or more comorbidities. CONCLUSIONS: BTB
serves as a unique sample for examination of contributors to health utility in
depressed homebound African American elders. Mobility, depression severity,
and number of comorbidities were significant predictors of health utility in this
population.
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OBJECTIVES: Compliance to treatment in schizophrenia is important to avoid re-
lapse and hospitalization. There is evidence that satisfaction to treatment is posi-
tively associatedwith adherence.We studied patient and physician preference and
satisfaction for different forms of administration of antipsychotic treatment and
drivers behind. METHODS: A non-interventional study including adult patients
diagnosed with schizophrenia and other schizoaffective disorders using long-term
therapy with either atypical orals, atypical LAI (long acting injectables) or other
typical LAI were included. One face-to-facemeetingwas conductedwere a number
of questionnaires were answered by the patient and the physician, MSQ (Medical
Satisfaction Questionnaire), CGI-Severity, DAI (Drug Attitude Inventory) as well as
current and previous medication, adherence, adverse reactions and other back-
ground variables. The hypothesis was that non-.inferiority in MSQ scale between
Atypical LAIs and Atypical oral treatment exist. Statistical method was analysis of
variance with a 95% confidence interval. RESULTS: A total of 265 patients in Swe-
den, Finland, Norway and Denmark with a stable disease during the last three
months were included. Significant differences were observed between oral treat-
ment and injectables in age and time to diagnosis, and were therefore adjusted for
in our analysis. Non-inferiority could be established in theMSQ (primary objective).
The hypothesis of superiority was confirmed in DAI scale, were both Atypical Oral
and Atypical LAI where significant better (p0.0001 and p0.0003) compared to
Typical LAI. Patient own assessment of adherence showed that patients on LAI
were more adherent than patients on Atypical oral treatment, while no difference
between the two LAI existed. CONCLUSIONS: These results suggest that patient
satisfaction with their drug therapy is not determined by the administration form.
Physicians need to have a good understanding of patients preferences and satis-
faction to therapy when initiating drug therapy.
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OBJECTIVES: To assess family functioning from patients’ and partners’ perspec-
tives to better understand the impact of depression on family functioning; To de-
velop and test patient and partner versions of a new self-reported measure, the
Depression and Family Functioning Scale (DFFS), for use in clinical trials.
METHODS: First, 32 in-depth interviews were conducted separately with adults
withmoderate-to-severeMDDand their respective partners to 1) gather qualitative
data describing the impact of depression on family functioning, and 2) identify
constructs relevant to measuring this impact. Next, based on the interview results
and a targeted literature review conducted to supplement these results, 26 items
were drafted to address each aspect of family functioning likely to be affected by
depression. Questionnaire items were then tested and refined through two itera-
tive sets of cognitive interviews with a total of 15 MDD patients and 15 partners of
MDDpatients to allow for enhanced comprehension of questionnaire items, aswell
as optimization of the recall period and response scales used in the final DFFS.
RESULTS: Depression negatively affects family functioning, most notably through
poorer communication, increased conflicts, decreased family interaction, and de-
creased intimacy. Family functioning constructsmost commonly referenced in the
literature review included communication, satisfaction, and cohesion. Draft DFFS
items generally tested well and only minor modifications were made to the items
after the second set of interviews to further facilitate comprehension and accurate
responses. Both patients and partners found the final 15 DFFS items important and
relevant. CONCLUSIONS: Depression negatively affects family functioning in mul-
tiple ways. The DFFS is a brief scale designed to evaluate depression’s impact on
family functioning in patients with MDD and their partners. The DFFS has the
potential to provide unique and important information facilitating more compre-
hensive evaluation of new treatments in clinical trial settings.
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OBJECTIVES: Caregivers of people with schizophrenia experience economic and
humanistic burden which not only affects their quality of life (QoL) and function-
ing, but also compromises the continuity of care to the patients. The goal is to
provide a comprehensive reviewof studies that have assessed the caregiver burden
and to identify instruments that measure caregiver burden in schizophrenia.
METHODS: A systematic literature review was conducted from January 2000 -
December 2010 using a number of medical databases. Studies assessing care-
giver burden were identified after applying the inclusion/exclusion criteria. In
addition, the review also identified instruments along with their psychometric
evaluation. Clinical and review studies were excluded from the systematic
review. RESULTS: The review yielded 22 studies that focused on psychoeduca-
tional interventions designed for caregivers, predictors, mediators and conse-
quences of caregiver burden, and cultural/ethnic differences in caregiving. The
most important predictors of caregiver burden were contact time with the patient,
cohabitationwith the patient, and coping styles of the caregiver. The consequences
of caregiver burdenweremostly psychosocial in nature. The review also yielded 13
instruments (1 generic, 12 condition-specific). The most common domains in-
cluded impact on daily life/household tasks, social life, psychological well-being,
economic burden, time constraints imposed and relationship with healthcare pro-
fessionals. A review of the psychometric properties of these instruments indicated
good reliability (Cronbach’s alpha 0.6 – 0.94). However, responsiveness of the in-
struments was not discussed. CONCLUSIONS: Caregivers play a crucial role in the
management of schizophrenia and with the increasing recognition of caregiver
burden, it is important for healthcare professionals to consider the health and
well-being of caregivers. Understanding the nature and extent of caregiver burden
will facilitate the development of appropriate interventions that can help improve
caregivers’ quality of life (QoL) and functioning.
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OBJECTIVES: To compare quality of life, work productivity loss, and resource use
between respondents diagnosed or not diagnosed with depression and/or experi-
encing sleep difficulties.METHODS:Datawere analyzed fromKantar Health’s 2010
US National Health andWellness Survey, a nationwide survey of adults (18 years
old). Outcome variables were components of the SF-12v2 HRQoL instrument: men-
tal and physical component summary scores (MCS and PCS) and SF6D health util-
ities (measuring health status).Work productivity loss (employed individuals only)
and activity impairment were assessed using the Work Productivity and Activity
Impairment questionnaire. Resource use was measured by the number of tradi-
tional health care provider visits, ER visits and hospitalizations. Linear regressions
and negative binomial regressions, controlling for patient demographics and co-
morbidities, were applied as appropriate. RESULTS: A total of 75,000 respondents
completed the survey, including those diagnosed with depression and experienc-
ing sleep difficulties (n  10,119), depressed without sleep difficulties (n  1,717),
not depressed with sleep difficulties (n  33,341), and not depressed with no sleep
difficulties (n  29,823). Compared with the other groups, those with both depres-
sion and sleep difficulties had poorer PCS, MCS and health utility scores; greater
lost work productivity and activity impairment; and significantly more traditional
healthcare provider visits, ER visits and hospitalizations (all p-values0.05). De-
A195V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 1 – A 2 1 4
